SEOUL, June 27 (Korea Bizwire) — South Korea’s first COVID-19 vaccine candidate, developed by SK Bioscience Co., has received an approval recommendation from a government advisory group of pharmaceutical experts, officials said Monday, pushing the vaccine candidate one step closer to commercial launch. The Ministry of Food and Drug Safety said GBP510, the vaccine candidate [...]
SEOUL, May 23 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. said Monday it has secured a US$31.3 million deal from the Pan American Health Organization (PAHO) to supply chickenpox vaccines to Latin American countries. SK Bioscience said it has recently delivered its first batch of shipments of SKY Varicella, the company’s chickenpox [...]
SEOUL, March 31 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. will expand its business portfolio to secure a new growth engine with the aim of becoming a global top-tier biotechnology firm by 2025, its chief said Thursday. Celebrating the one-year anniversary of its initial public offering (IPO) on the main bourse, the [...]
SEOUL, Dec. 24 (Korea Bizwire) — SK Bioscience Co., a vaccine unit of South Korea’s SK Group, said Friday it has extended an agreement to manufacture a component of the U.S.-based biotechnology company Novavax Inc.’s COVID-19 vaccine by one more year. Under the extended agreement, SK Bioscience will reserve additional manufacturing capacity to produce antigen, [...]
SEOUL, Dec. 18 (Korea Bizwire) — South Korean drugmakers have begun the process to develop COVID-19 vaccines that are effective against the new omicron variant amid concerns that the highly transmissible strain may become a dominant one soon. As the omicron variant fuels fears around the world that the pandemic could rage during the winter [...]
SEOUL, Oct. 6 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Wednesday it has signed an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to extend capacity reservations for manufacturing COVID-19 vaccines by the end of 2022. The agreement was signed between SK Bioscience CEO Ahn Jae-yong and Richard Hatchett, CEO of [...]
SEOUL, Aug. 30 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Monday it has begun the phase three clinical trial of its COVID-19 vaccine candidate. GBP510, under development by SK Bioscience, a unit of the country’s No. 2 family-controlled conglomerate SK Group, was administered to the first participant. It comes nearly three weeks [...]
SEOUL, Aug. 10 (Korea Bizwire) – South Korean drugmaker SK Bioscience Co. has won an approval to conduct the phase three clinical trial of its COVID-19 vaccine candidate, drug authorities said Tuesday. The Ministry of Food and Drug Safety said GBP510, under development by SK Bioscience, a unit of the country’s No. 2 family-controlled conglomerate [...]
SEOUL, June 21 (Korea Bizwire) — SK Bioscience Co., a major South Korean pharmaceutical firm, said Monday it plans to invest 150 billion won (US$132 million) through 2024 to expand its production capacity of COVID-19 vaccines. SK Bioscience said the investment is meant to increase the production capacity of the production line based in Andong, [...]
SEOUL, May 23 (Korea Bizwire) – South Korea, touted as one of most successful countries in containing the new coronavirus pandemic without lockdowns, is gearing up for its next step to emerge as a global vaccine hub, with four COVID-19 vaccines already being or set to be produced here. The country’s vision to become a [...]